Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedJan 15, 2026
DataAggregated Company Financials
Companies316
  • 7D-0.04%
  • 3M23.3%
  • 1Y31.5%
  • YTD2.5%

Last week, the Pharma industry hasn't moved much but Johnson & Johnson is up 5.3% in that time. As for the the longer term, the industry is up 31% over the past 12 months. As for the next few years, earnings are expected to grow by 13% per annum.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 15 Jan 2026US$2.3tUS$402.6bUS$71.5b20.9x32x5.7x
Sat, 13 Dec 2025US$2.2tUS$402.8bUS$71.4b20x30.5x5.4x
Mon, 10 Nov 2025US$2.0tUS$396.3bUS$70.8b17.9x27.7x4.9x
Wed, 08 Oct 2025US$1.9tUS$387.6bUS$61.0b18.3x31.4x4.9x
Fri, 05 Sep 2025US$1.8tUS$387.9bUS$61.0b18.9x29.2x4.6x
Sun, 03 Aug 2025US$1.7tUS$382.0bUS$54.8b17.8x31.5x4.5x
Tue, 01 Jul 2025US$1.7tUS$382.7bUS$61.2b17.5x28x4.5x
Thu, 29 May 2025US$1.7tUS$382.6bUS$61.2b17.6x27.2x4.4x
Sat, 26 Apr 2025US$1.8tUS$379.6bUS$63.1b16.2x28.1x4.7x
Mon, 24 Mar 2025US$1.9tUS$381.1bUS$41.3b17x45.6x4.9x
Wed, 19 Feb 2025US$1.8tUS$381.0bUS$39.0b18.2x46.9x4.8x
Fri, 17 Jan 2025US$1.8tUS$369.3bUS$31.2b18.8x56.7x4.8x
Sun, 15 Dec 2024US$1.8tUS$373.8bUS$30.6b18.4x59.4x4.9x
Tue, 12 Nov 2024US$1.9tUS$373.6bUS$30.6b20.9x62x5.1x
Thu, 10 Oct 2024US$2.0tUS$364.1bUS$25.2b18.4x79.2x5.5x
Sat, 07 Sep 2024US$2.0tUS$364.1bUS$25.5b17.8x78.9x5.5x
Mon, 05 Aug 2024US$1.9tUS$359.3bUS$22.1b15.8x86.8x5.3x
Wed, 03 Jul 2024US$2.0tUS$357.6bUS$13.8b15.4x142.3x5.5x
Fri, 31 May 2024US$1.9tUS$358.3bUS$14.1b15.7x132.2x5.2x
Sun, 28 Apr 2024US$1.8tUS$359.5bUS$17.5b22.4x102.8x5x
Tue, 26 Mar 2024US$1.9tUS$355.3bUS$22.6b19.2x82.6x5.3x
Thu, 22 Feb 2024US$1.9tUS$355.0bUS$23.9b28.7x78.6x5.3x
Sat, 20 Jan 2024US$1.7tUS$375.2bUS$33.9b27.7x51.6x4.7x
Mon, 18 Dec 2023US$1.6tUS$375.1bUS$33.9b26.7x48.6x4.4x
Wed, 15 Nov 2023US$1.6tUS$375.6bUS$34.1b28.3x47.9x4.4x
Fri, 13 Oct 2023US$1.7tUS$381.8bUS$43.8b17.2x39x4.5x
Sun, 10 Sep 2023US$1.8tUS$381.8bUS$43.9b19.1x41.6x4.8x
Tue, 08 Aug 2023US$1.7tUS$379.5bUS$42.9b20.5x39.7x4.5x
Thu, 06 Jul 2023US$1.7tUS$392.8bUS$60.2b19.1x28.9x4.4x
Sat, 03 Jun 2023US$1.7tUS$393.0bUS$60.6b18.9x28.3x4.4x
Mon, 01 May 2023US$1.7tUS$400.2bUS$62.2b17.4x27x4.2x
Wed, 29 Mar 2023US$1.6tUS$401.2bUS$69.5b14.8x22.4x3.9x
Fri, 24 Feb 2023US$1.6tUS$401.7bUS$68.4b17.8x23.4x4x
Sun, 22 Jan 2023US$1.7tUS$403.7bUS$70.6b17.7x23.9x4.2x
Price to Earnings Ratio

23.9x


Total Market Cap: US$1.7tTotal Earnings: US$70.6bTotal Revenue: US$403.7bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 53x202420252026
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 32.0x which is lower than its 3-year average PE of 53.0x.
  • The 3-year average PS ratio of 4.8x is lower than the industry's current PS ratio of 5.7x.
Past Earnings Growth
  • Both revenue and earnings for companies in the Pharmaceuticals industry have remained mostly flat over the last three years.
  • This means that sales and the cost of doing business have remained relatively consistent over this period and subsequently, so have profits.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.18%
Healthcare-1.03%
Pharma-0.039%
Pharma-0.039%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
JNJ Johnson & JohnsonUS$218.555.3%
+US$26.6b		50.8%PE21x
MRK MerckUS$111.012.2%
+US$6.0b		10.9%PE14.5x
PFE PfizerUS$25.581.2%
+US$1.7b		-2.4%PE14.8x
GPCR Structure TherapeuticsUS$84.3325.9%
+US$1.2b		212.6%PB7.6x
ALMS AlumisUS$24.3435.8%
+US$1.2b		214.9%PS137.2x

Latest News

LLY
US$1,073.29
Eli Lilly
7D
-3.1%
1Y
43.7%
JNJ
US$218.55
Johnson & Johnson
7D
5.3%
1Y
50.8%
RPRX
US$40.21
Royalty Pharma
7D
-2.9%
1Y
30.8%
PFE
US$25.58
Pfizer
7D
1.2%
1Y
-2.4%
NUVB
US$6.31
Nuvation Bio
7D
-28.6%
1Y
142.7%
AQST
US$3.52
Aquestive Therapeutics
7D
-43.5%
1Y
8.6%
ELAN
US$24.44
Elanco Animal Health
7D
7.0%
1Y
106.2%

ELAN: New Pet Health Launches And Margin Expansion Plans May Support Upside

Our analyst fair value estimate for Elanco Animal Health has been raised from US$18.00 to about US$29.84. This change reflects higher Street price targets in the US$24 to US$27 range and analyst expectations for stronger revenue growth, wider margins, and improved leverage supported by recent product launches.
VTRS
US$13.15
Viatris
7D
5.5%
1Y
15.5%

VTRS: Affordable Medicines Theme And Pipeline Milestones Will Support Future Cash Returns

Analysts have nudged their price target on Viatris higher from US$15 to US$16, citing continued interest in the affordable medicines theme heading into 2026 as a key support for the updated fair value estimate of about US$12.67 and a slightly higher implied future P/E of about 35.55x. Analyst Commentary Recent research on Viatris has centered on the updated US$16 price target and how it lines up with the affordable medicines theme, the implied fair value of about US$12.67, and the higher future P/E of roughly 35.55x.
MRK
US$111.01
Merck
7D
2.2%
1Y
10.9%

MRK: Cidara Flu Deal Will Likely Highlight Overstated Long Term Hopes

Narrative Update The analyst price target for Merck has moved higher to a range of about $105 to $135. Analysts point to sector re-ratings, recent upgrades to Outperform, and confidence in the company’s product pipeline and deal activity as key drivers of their updated views.
INDV
US$33.63
Indivior
7D
-6.3%
1Y
189.9%
CRMD
US$7.09
CorMedix
7D
-36.5%
1Y
-40.4%
ALMS
US$24.34
Alumis
7D
35.8%
1Y
214.9%
RGC
US$35.17
Regencell Bioscience Holdings
7D
-33.5%
1Y
27,512.9%
BLTE
US$153.68
Belite Bio
7D
-6.4%
1Y
179.9%
GPCR
US$84.33
Structure Therapeutics
7D
25.9%
1Y
212.6%
LQDA
US$39.99
Liquidia
7D
25.9%
1Y
219.7%

Liquidia Corporation (NASDAQ:LQDA) Looks Just Right With A 30% Price Jump

Dec 06
Liquidia Corporation (NASDAQ:LQDA) Looks Just Right With A 30% Price Jump